Dans cette 72e baladodiffusion, les Drs Alexandre Mutchmore et Dusanka Grbic discutent du sémaglutide comme traitement de la stéatohépatite liée à une dysfonction métabolique, en plus de réviser la littérature médicale de mai et juin 2025.

Quiz clinique (3 min 33), présentation principale (4 min 12), critique (29 min 25), retour sur le cas clinique (36 min 29), autres articles (39 min 00), réponse au quiz clinique (43 min 39)

Référence principale :

Sanyal AJ, Newsome PN, Kliers I, Ostergaard LH, Long MT, Kjaer MS, et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2025;392(21):2089-99. PubMed PMID: 40305708.

Articles associés : 

Simon TG. Semaglutide for Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2025;392(21):2160-1. PubMed PMID: 40466070.

Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024;390(6):497-509. PubMed PMID: 38324483.

Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-835. PubMed PMID: 36727674.

EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492-542. PubMed PMID: 38851997.

Israelsen M, Francque S, Tsochatzis EA, Krag A. Steatotic liver disease. Lancet. 2024;404(10464):1761-1778. PubMed PMID: 39488409.

Sanyal AJ, Bedossa P, Fraessdorf M, Neff GW, Lawitz E, Bugianesi E, et al 1404-0043 Trial Investigators. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N Engl J Med. 2024;391(4):311-319. PubMed PMID: 38847460.

Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E, et al; SYNERGY-NASH Investigators. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N Engl J Med. 2024;391(4):299-310. PubMed PMID: 38856224.

Lin J, Huang Y, Xu B, Gu X, Huang J, Sun J, et al. Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial. BMJ. 2025;389:e083735. PubMed PMID: 40467095.

Autres articles d’intérêt récent : 

Humbert M, McLaughlin VV, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, et al. Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death. N Engl J Med. 2025;392(20):1987-2000. PubMed PMID: 40167274.

Bonaca MP, Catarig AM, Houlind K, Ludvik B, Nordanstig J, Ramesh CK, et al. Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial. Lancet. 2025;405(10489):1580-93. PubMed PMID: 40169145.

Blockmans D, Penn SK, Setty AR, Schmidt WA, Rubbert-Roth A, Hauge EM, et al. A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis. N Engl J Med. 2025;392(20):2013-24. PubMed PMID: 40174237.

Laffin LJ, Kopjar B, Melgaard C, Wolski K, Ibbitson J, Bhikam S, et al. Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension. N Engl J Med. 2025;392(18):1813-23. PubMed PMID: 40267417.

Garrison SR, Bakal JA, Kolber MR, Korownyk CS, Green LA, Kirkwood JEM, et al. Antihypertensive Medication Timing and Cardiovascular Events and Death: The BedMed Randomized Clinical Trial. JAMA. 2025;333(23):2061-72. PubMed PMID: 40354045.

Herrmann JJ, Brunner-La Rocca HP, Baltussen L, Beckers-Wesche F, Bekkers S, Bellersen L, et al. Liberal fluid intake versus fluid restriction in chronic heart failure: a randomized clinical trial. Nat Med. 2025;31(6):2062-8. PubMed PMID: 40159556.

Richeldi L, Azuma A, Cottin V, Kreuter M, Maher TM, Martinez FJ, et al. Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis. N Engl J Med. 2025;392(22):2193-202. PubMed PMID: 40387033.

Maher TM, Assassi S, Azuma A, Cottin V, Hoffmann-Vold AM, Kreuter M, et al. Nerandomilast in Patients with Progressive Pulmonary Fibrosis. N Engl J Med. 2025;392(22):2203-14. PubMed PMID: 40388329.

Lee CJ, Ihm SH, Shin DH, Jeong JO, Kim JH, Chun KH, et al. Spironolactone vs Amiloride for Resistant Hypertension: A Randomized Clinical Trial. JAMA. 2025;333(23):2073-82. PubMed PMID: 40366680.

Guides de pratique : 

Goupil R, Tsuyuki RT, Santesso N, Terenzi KA, Habert J, Cheng G, et al. Hypertension Canada guideline for the diagnosis and treatment of hypertension in adults in primary care. CMAJ. 2025;197(20):E549-E64. PubMed PMID: 40419299

Tobe SW, Bajaj HS, Tangri N, Jain R, Pham T, Beaudin V, et al. Chronic Kidney Disease in Diabetes: A Clinical Practice Guideline. Can J Diabetes. 2025;49(2):73-86. PubMed PMID: 40382193.

Mir H, Eisenberg MJ, Benowitz NL, Cowley E, Heshmati J, Jha P, et al. Canadian Cardiovascular Society Clinical Practice Update on Contemporary Approaches to Smoking Cessation. Can J Cardiol. 2025;41(5):797-812. PubMed PMID: 40340054.

Osiowy C, Alvarez F, Coffin CS, Cooper CL, Fung SK, Ko HH, et al. The management of chronic hepatitis B: 2025 Guidelines update from the Canadian Association for the Study of the Liver and Association of Medical Microbiology and Infectious Disease Canada. Canadian Liver Journal. 2025;8(2):368-401. 

Rao SV, O’Donoghue ML, Ruel M, Rab T, Tamis-Holland JE, Alexander JH, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2025;85(22):2135-237. PubMed PMID: <a href="https://pu